FDA
-
-
-
-
-
-
-
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
-
-
-
-
-
329,028 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

